Anglo-Swiss life sciences investment company Medicxi has raised $400 million for its fourth fund, which will focus on supporting 'asset-centric' companies at all stages of
Moncef Slaoui has stepped down from positions at three more companies, shortly after being dismissed from a firm owned by GlaxoSmithKline for alleged sexual harassment.
GlaxoSmithKline has fired its former research boss Moncef Slaoui from the board of Galvani Bioelectronics, a company it majority owns, after an internal investigation found he sexually hara
Putting together a quarter-billion dollar pharma company from ten mergers in four months is not for the faint-hearted – but that’s what biotech investment guru Francesco de Rubertis has ach
New $300m fund aimed at helping European biotechs to grow, providing alternative to an IPO or 'generally suboptimal' licensing or big pharma acquisition
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio